Zimmer Biomet (NYSE:ZBH) Sets New 1-Year Low – Time to Sell?

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) shares reached a new 52-week low on Wednesday . The company traded as low as $84.91 and last traded at $85.6350, with a volume of 380833 shares traded. The stock had previously closed at $85.99.

Wall Street Analysts Forecast Growth

ZBH has been the subject of a number of analyst reports. Robert W. Baird reiterated a “neutral” rating and issued a $100.00 price target (down previously from $117.00) on shares of Zimmer Biomet in a research note on Tuesday, December 16th. Canaccord Genuity Group cut their price objective on shares of Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating for the company in a report on Monday, November 10th. Wall Street Zen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zimmer Biomet in a report on Wednesday, January 21st. Finally, Johnson Rice set a $112.00 price objective on Zimmer Biomet in a research note on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $107.24.

Zimmer Biomet Stock Performance

The company has a quick ratio of 1.39, a current ratio of 2.43 and a debt-to-equity ratio of 0.59. The firm has a 50 day moving average of $91.25 and a 200-day moving average of $96.15. The company has a market cap of $16.99 billion, a P/E ratio of 21.21, a PEG ratio of 2.22 and a beta of 0.62.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.88 by $0.02. The firm had revenue of $2 billion during the quarter, compared to analysts’ expectations of $2.01 billion. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. The company’s revenue was up 9.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.74 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Tuesday, December 30th will be paid a dividend of $0.24 per share. The ex-dividend date is Tuesday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. Zimmer Biomet’s payout ratio is presently 23.76%.

Institutional Trading of Zimmer Biomet

Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Zimmer Biomet by 0.9% in the second quarter. Vanguard Group Inc. now owns 23,251,295 shares of the medical equipment provider’s stock valued at $2,120,751,000 after buying an additional 198,370 shares during the last quarter. Dodge & Cox raised its holdings in shares of Zimmer Biomet by 5.1% during the third quarter. Dodge & Cox now owns 23,216,173 shares of the medical equipment provider’s stock worth $2,286,793,000 after purchasing an additional 1,118,710 shares during the last quarter. Capital International Investors lifted its position in Zimmer Biomet by 11.5% during the third quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock valued at $743,749,000 after purchasing an additional 778,467 shares during the period. American Century Companies Inc. grew its position in Zimmer Biomet by 8.7% during the 2nd quarter. American Century Companies Inc. now owns 5,709,370 shares of the medical equipment provider’s stock worth $520,752,000 after purchasing an additional 458,903 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Zimmer Biomet by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 5,124,776 shares of the medical equipment provider’s stock valued at $465,480,000 after buying an additional 69,485 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.